JP2022500485A5 - - Google Patents
Info
- Publication number
- JP2022500485A5 JP2022500485A5 JP2021517311A JP2021517311A JP2022500485A5 JP 2022500485 A5 JP2022500485 A5 JP 2022500485A5 JP 2021517311 A JP2021517311 A JP 2021517311A JP 2021517311 A JP2021517311 A JP 2021517311A JP 2022500485 A5 JP2022500485 A5 JP 2022500485A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- hours
- dosage form
- unit dosage
- serum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862737285P | 2018-09-27 | 2018-09-27 | |
| US62/737,285 | 2018-09-27 | ||
| US201962834513P | 2019-04-16 | 2019-04-16 | |
| US62/834,513 | 2019-04-16 | ||
| PCT/US2019/053413 WO2020069288A1 (en) | 2018-09-27 | 2019-09-27 | Grapiprant unit dosage forms |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022500485A JP2022500485A (ja) | 2022-01-04 |
| JP2022500485A5 true JP2022500485A5 (https=) | 2022-10-05 |
Family
ID=69953354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021517311A Pending JP2022500485A (ja) | 2018-09-27 | 2019-09-27 | グラピプラント単位剤形 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210353648A1 (https=) |
| EP (1) | EP3856177A4 (https=) |
| JP (1) | JP2022500485A (https=) |
| CN (1) | CN113260363A (https=) |
| CA (1) | CA3113468A1 (https=) |
| WO (1) | WO2020069288A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021522211A (ja) | 2018-04-16 | 2021-08-30 | アリーズ セラピューティクス， インコーポレイテッド | Ｅｐ４阻害剤およびその使用 |
| US20210315909A1 (en) | 2018-07-11 | 2021-10-14 | Arrys Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| CN115697317A (zh) * | 2020-04-08 | 2023-02-03 | 株式会社AskAt | Ep4受体拮抗剂用于治疗肝癌、黑色素瘤、淋巴瘤和白血病的应用 |
| CN115919756B (zh) * | 2022-10-19 | 2024-08-23 | 梅州市珍宝金柚实业有限公司 | 一种金柚原浆口服液及其制备方法和用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7998505B2 (en) * | 2006-10-27 | 2011-08-16 | Fmc Corporation | Dry granulation binders, products, and use thereof |
| EP2965756B1 (en) * | 2009-04-22 | 2018-10-10 | AskAt Inc. | Selective ep4 receptor antagonistic substance for treatment of cancer |
| CN103764167A (zh) * | 2011-07-15 | 2014-04-30 | 尤法玛有限公司 | 包含抗酸剂、麻醉剂以及含二氧化硅和二氧化钛的无机基质的口服组合物 |
| IN2013MU02370A (https=) * | 2013-07-16 | 2015-06-19 | Cadila Pharmaceuticals Ltd | |
| PT3113774T (pt) * | 2014-03-06 | 2022-02-28 | Elanco Animal Health Incorporated | Composições de grapiprant e métodos de utilização das mesmas |
-
2019
- 2019-09-27 EP EP19865430.3A patent/EP3856177A4/en not_active Withdrawn
- 2019-09-27 WO PCT/US2019/053413 patent/WO2020069288A1/en not_active Ceased
- 2019-09-27 CN CN201980072471.4A patent/CN113260363A/zh active Pending
- 2019-09-27 CA CA3113468A patent/CA3113468A1/en active Pending
- 2019-09-27 JP JP2021517311A patent/JP2022500485A/ja active Pending
- 2019-09-27 US US17/278,601 patent/US20210353648A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022500485A5 (https=) | ||
| JP2018510178A5 (https=) | ||
| JP7754799B2 (ja) | てんかん重積状態の治療に使用するためのガナキソロン | |
| JP2023552700A5 (https=) | ||
| JP2010065060A (ja) | 心不全処置のための複合治療 | |
| JP2024019691A (ja) | 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法 | |
| CN110123771A (zh) | 药物组合药物 | |
| JP2005528429A (ja) | 活性成分の徐放性を有するオクスカルバゼピン含有薬学的組成物 | |
| JP6509729B2 (ja) | 慢性腎臓病の進行抑制又は改善剤 | |
| JP2023139157A (ja) | 抗線維化療法を投与する方法 | |
| IL272834B1 (en) | Compositions of amantadine, their preparation, and methods of use | |
| JP2019533672A (ja) | メラトニンミニタブレットおよびその製造方法 | |
| JP2004091473A (ja) | 色素沈着改善治療薬 | |
| JP2022177119A5 (https=) | ||
| AU2011339150B2 (en) | Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof | |
| JP2010106019A (ja) | リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および／または症状軽減剤 | |
| CN112912070A (zh) | 夜间多尿的治疗或预防剂 | |
| AU2023397768A1 (en) | Stat3 inhibitors for use in the treatment of non-viral liver cancer | |
| WO2019004465A1 (ja) | ペマフィブラートを含有する医薬 | |
| JP6420923B1 (ja) | 医薬 | |
| CN115315258A (zh) | 肾功能保护剂 | |
| JP2016514125A (ja) | バルサルタン及びロスバスタチンカルシウムを含む複合製剤及びその製造方法 | |
| TWI744858B (zh) | 治療精神疾病之控釋藥物組合物和方法 | |
| EP3790550A1 (en) | Pharmaceutical composition and method for acute on chronic liver failure | |
| US20250073214A1 (en) | Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder |